Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3533847 | 0.86 | ALDH1A1 (0.35) | ALDH1A1L3MBTL1TDP1GPR119MEN1 | |
| SCHEMBL3313222 | 0.85 | GPR119 (0.32) | F10CYP4F2CYP4A11GPR119 | |
| SCHEMBL22557067 | 0.83 | EPHX2 (0.42) | EPHX2EPHX1ALDH1A1 | |
| SCHEMBL30741144 | 0.83 | BRD4 (0.43) | CYP4F2CYP4A11EPHX1L3MBTL1GPR119 | |
| SCHEMBL23387564 | 0.83 | GPR119 (0.38) | EPHX2EPHX1ALDH1A1GPR119 | |
| SCHEMBL23277546 | 0.83 | GPR119 (0.34) | F10CYP4F2CYP4A11EPHX2HDAC3 | |
| SCHEMBL20323516 | 0.82 | MAPT (0.48) | CYP4F2CYP4A11ALDH1A1GPR119MEN1 | |
| SCHEMBL27035717 | 0.82 | AOC2 (0.40) | ALDH1A1GPR119 | |
| SCHEMBL17235749 | 0.81 | TEAD1 (0.45) | GPR119 | |
| SCHEMBL31637322 | 0.81 | CYP4F2 (0.42) | CYP4F2CYP4A11HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331035-B2 | Bicyclic compound and use thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-06-17 | — | — | US | disclosed |
| EP-4050006-B1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2025-01-01 | — | — | EP | disclosed |
| US-12162836-B2 | N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds and their therapeutic use | Modern Biosciences Limited (GB) | 2024-12-10 | — | — | US | disclosed |
| US-11958837-B2 | Quinazolinones as PARP14 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20240051951-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2024-02-15 | — | — | US | disclosed |
| US-20230286965-A1 | BICYCLIC COMPOUND AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-09-14 | — | — | US | disclosed |
| US-11725001-B2 | Bicyclic compound and use thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2023-08-15 | — | — | US | disclosed |
| EP-4212515-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-3728207-B1 | QUINAZOLINONES AS PARP14 INHIBITORS | RIBON THERAPEUTICS INC (US) | 2023-02-01 | — | — | EP | disclosed |
| US-20230022917-A1 | N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE | ISTESSO THERAPEUTICS LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
| WO-2021066578-A1 | BICYCLIC COMPOUND AND USE THEREOF | 에스케이바이오팜 주식회사 | 2021-04-08 | — | — | WO | disclosed |
| EP-3728207-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | Ribon Therapeutics Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| WO-2020212581-A1 | N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE | Modern Biosciences Limited (GB) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020212581-A1 | N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE | Modern Biosciences Limited (GB) | 2020-10-22 | — | — | WO | disclosed |
| US-20200247788-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | ABBVIE BIOTECHNOLOGY LTD (BM) | 2020-08-06 | — | — | US | disclosed |
| US-10562891-B2 | Quinazolinones as PARP14 inhibitors | Ribon Therapeutics Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190194174-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | ABBVIE BIOTECHNOLOGY LTD (BM) | 2019-06-27 | — | — | US | disclosed |
| US-20100105727-A1 | NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARTION THEREOF | DONG-A-PHARM. CO., LTD. (KR) | 2010-04-29 | — | — | US | disclosed |
| EP-2137152-A1 | NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | Dong-A Pharm.Co., Ltd. (KR) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008114971-A1 | NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | DONG-A PHARM. CO., LTD. (KR) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162836-B2 | N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds and their therapeutic use | MCL1, BCL9, BCL9L | F10 4819/4885CYP4F2 4703/4885CYP4A11 2212/4885 |
| US-11958837-B2 | Quinazolinones as PARP14 inhibitors | PARP14, PARP15, PARP11 | F10 3683/4885CYP4F2 3424/4885CYP4A11 2222/4885 |
| US-20200247788-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | PARP14, PARP15, PARP11 | F10 3683/4885CYP4F2 3424/4885CYP4A11 2222/4885 |
| US-20100105727-A1 | NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARTION THEREOF | HTR4, HTR1A, TPH1 | F10 1871/4885CYP4F2 565/4885CYP4A11 568/4885 |
| US-12331035-B2 | Bicyclic compound and use thereof | PRMT5, PRMT6, PRMT1 | F10 4691/4885CYP4F2 3092/4885CYP4A11 1948/4885 |
| US-20240051951-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT1 | F10 4737/4885CYP4F2 3457/4885CYP4A11 2367/4885 |
| US-10562891-B2 | Quinazolinones as PARP14 inhibitors | PARP14, PARP15, PARP11 | F10 3683/4885CYP4F2 3424/4885CYP4A11 2222/4885 |
| US-20230022917-A1 | N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE | MCL1, BCL9, BCL9L | F10 4819/4885CYP4F2 4703/4885CYP4A11 2212/4885 |
| US-20230286965-A1 | BICYCLIC COMPOUND AND USE THEREOF | PRMT5, PRMT6, PRMT8 | F10 4797/4885CYP4F2 3819/4885CYP4A11 3074/4885 |
| US-11725001-B2 | Bicyclic compound and use thereof | PRMT5, PRMT6, PRMT1 | F10 4737/4885CYP4F2 3457/4885CYP4A11 2367/4885 |
| US-20190194174-A1 | QUINAZOLINONES AS PARP14 INHIBITORS | PARP14, PARP15, PARP11 | F10 3683/4885CYP4F2 3424/4885CYP4A11 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.